This week, we will discuss whether the time has come to add mineralocorticoid antagonism to the RAS armamentarium. Can we surmount the hyperkalemia which is the commonest problem with these drugs? Let’s find out with FIDELIO.
Background
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
Background
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
